|7.84 0.03 (0.38%)||12-06 16:00|
|Targets||6-month :||9.8||1-year :||10.58|
|Resists||First :||8.39||Second :||9.06|
|Supports||First :||7.31||Second :||6.08|
|MAs||MA(5) :||7.77||MA(20) :||7.96|
|MA(100) :||7.66||MA(250) :||6.18|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||57.9||D(3) :||50.2|
|52-week||High :||9.52||Low :||2.2|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMNM ] has closed below upper band by 49.3%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||8.01 - 8.05||8.05 - 8.08|
|Low:||7.64 - 7.69||7.69 - 7.73|
|Close:||7.77 - 7.84||7.84 - 7.9|
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||43 (M)|
|Shares Float||25 (M)|
|Held by Insiders||31.7 (%)|
|Held by Institutions||15.4 (%)|
|Shares Short||428 (K)|
|Shares Short P.Month||198 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.5|
|Profit Margin||-215.5 %|
|Operating Margin||-130 %|
|Return on Assets (ttm)||-22.9 %|
|Return on Equity (ttm)||-150.7 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0.23|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||3 (M)|
|Levered Free Cash Flow||8 (M)|
|Price to Book value||15.68|
|Price to Sales||32.87|
|Price to Cash Flow||104.36|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|